Unit
Medizinische Onkologie und Hämatologie
ONKO · Dept. I
ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer
Leyland-Jones B, Maibach R, Price K, Coates A, Goldhirsch A, Gelber R, Pagani O, Viale G, Rae J, Regan M, Arnould L, Neven P, Harvey V, Gray K, Abramovitz M, Bouzyk M, Young B, Long B, Kammler R, Dell'Orto P, Biasi M, Thürlimann B, BIG 1-98 Collaborative Group. ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer. Breast Cancer Res Treat 2015; 154:543-55.
Nov 21, 2015ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer
Nov 21, 2015Breast Cancer Res Treat 2015; 154:543-55
Leyland-Jones Brian, Maibach Rudolf, Price Karen N, Coates Alan S, Goldhirsch Aron, Gelber Richard D, Pagani Olivia, Viale Giuseppe, Rae James M, Regan Meredith M, Arnould Laurent, Neven Patrick, Harvey Vernon, Gray Kathryn P, Abramovitz Mark, Bouzyk Mark, Young Brandon, Long Bradley, Kammler Roswitha, Dell'Orto Patrizia, Biasi Maria Olivia, Thürlimann Beat, BIG 1-98 Collaborative Group
Prognostic score for patients with advanced melanoma treated with ipilimumab
Diem S. Prognostic score for patients with advanced melanoma treated with ipilimumab. European Journal of Cancer 2015
Nov 18, 2015Prognostic score for patients with advanced melanoma treated with ipilimumab
Nov 18, 2015European Journal of Cancer 2015
Diem Stefan
Knochenmarksversagen bei Tumorinfiltration bei einem Patienten mit Ästhesioneuroblastom, Mantelzell-Non-Hodgkin-Lymphom und Rektumkarzinom
Zürrer-Härdi U, Siano M, Broglie Däppen M. Knochenmarksversagen bei Tumorinfiltration bei einem Patienten mit Ästhesioneuroblastom, Mantelzell-Non-Hodgkin-Lymphom und Rektumkarzinom. Schweiz. Krebsbulletin 2015; 1:98-101.
Nov 9, 2015Knochenmarksversagen bei Tumorinfiltration bei einem Patienten mit Ästhesioneuroblastom, Mantelzell-Non-Hodgkin-Lymphom und Rektumkarzinom
Nov 9, 2015Schweiz. Krebsbulletin 2015; 1:98-101
Zürrer-Härdi Ursina, Siano Marco, Broglie Däppen Martina
Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial
Stahel R, Caspar C, Eckhardt K, Schmid R, Aebersold D, Gautschi O, Nagel W, Töpfer M, Krayenbuehl J, Ribi K, Ciernik L, Mordasini C, Zippelius A, Riesterer O, Xyrafas A, Opitz I, Beyeler M, Ochsenbein A, Früh M, Cathomas R, Nackaerts K, Peters S, Mamot C, Weder W. Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial. Lancet Oncol 2015; 16:1651-8.
Nov 2, 2015Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial
Nov 2, 2015Lancet Oncol 2015; 16:1651-8
Stahel Rolf A, Caspar Clemens B, Eckhardt Katrin, Schmid Ralph A, Aebersold Daniel M, Gautschi Oliver, Nagel Wolfgang, Töpfer Michael, Krayenbuehl Jerome, Ribi Karin, Ciernik Llja F, Mordasini Carlo, Zippelius Alfred, Riesterer Oliver, Xyrafas Alexandros, Opitz Isabelle, Beyeler Michael, Ochsenbein Adrian, Früh Martin, Cathomas Richard, Nackaerts Kristiaan, Peters Solange, Mamot Christoph, Weder Walter
Impact of Geographic Region on Benefit of Approved Anticancer Drugs Evaluated in International Phase III Clinical Trials
AlHashem H, Al-Mubarak M, Vera-Badillo F, Templeton A, Ocana A, Šeruga B, Amir E. Impact of Geographic Region on Benefit of Approved Anticancer Drugs Evaluated in International Phase III Clinical Trials. Clin Oncol (R Coll Radiol) 2015
Nov 2, 2015Impact of Geographic Region on Benefit of Approved Anticancer Drugs Evaluated in International Phase III Clinical Trials
Nov 2, 2015Clin Oncol (R Coll Radiol) 2015
AlHashem H Y, Al-Mubarak M, Vera-Badillo F E, Templeton Arnoud, Ocana A, Šeruga B, Amir E
Glioblastoma multiforme: Chameleon of neurology A case report
Prochnicki A, Zieglgänsberger D, Vehoff J, Müller S, Tettenborn B, Hundsberger T (2015). Glioblastoma multiforme: Chameleon of neurology A case report.
Oct 30, 2015Glioblastoma multiforme: Chameleon of neurology A case report
Oct 30, 2015SNG Tagung 2015
Prochnicki Anita, Zieglgänsberger Dominik, Vehoff Jochen, Müller Stefanie, Tettenborn Barbara, Hundsberger Thomas
Neurosonographic findings in non-systemic vasculitic neuropathy
Leupold D, Felbecker A, Tettenborn B, Hundsberger T (2015). Neurosonographic findings in non-systemic vasculitic neuropathy.
Oct 30, 2015Neurosonographic findings in non-systemic vasculitic neuropathy
Oct 30, 2015Jahrestagung 2015 Schweizerische Neurologische Gesellschaft
Leupold Daniela, Felbecker Ansgar, Tettenborn Barbara, Hundsberger Thomas
A Set of Activity-Based Probes to Visualize Human (Immuno)proteasome Activities
de Bruin G, Xin B, Kraus M, van der Stelt M, van der Marel G, Kisselev A, Driessen C, Florea B, Overkleeft H. A Set of Activity-Based Probes to Visualize Human (Immuno)proteasome Activities. Angew Chem Int Ed Engl 2015; 55:4199-203.
Oct 29, 2015A Set of Activity-Based Probes to Visualize Human (Immuno)proteasome Activities
Oct 29, 2015Angew Chem Int Ed Engl 2015; 55:4199-203
de Bruin Gerjan, Xin Bo Tao, Kraus Marianne, van der Stelt Mario, van der Marel Gijsbert A, Kisselev Alexei F, Driessen Christoph, Florea Bogdan I, Overkleeft Herman S
[Is prescription of a therapy costing 150,000 CHF reasonable?]
Peters S, von Moos R, Thürlimann B. [Is prescription of a therapy costing 150,000 CHF reasonable?]. Rev Med Suisse 2015; 11:1967-72.
Oct 21, 2015[Is prescription of a therapy costing 150,000 CHF reasonable?]
Oct 21, 2015Rev Med Suisse 2015; 11:1967-72
Peters Solange, von Moos Roger, Thürlimann Beat
Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel
Sonpavde G, Pond G, Templeton A, Fandi A, Tombal B, Rosenthal M, Armstrong A, Petrylak D. Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel. Eur Urol 2015
Oct 20, 2015Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel
Oct 20, 2015Eur Urol 2015
Sonpavde Guru, Pond Gregory R, Templeton Arnoud, Fandi Abderrahim, Tombal Bertrand, Rosenthal Mark, Armstrong Andrew J, Petrylak Daniel P
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)
Dabakuyo-Yonli T, Russell N, Roché H, Pruneri G, Penault Llorca F, Offersen B, Negreiros I, Michiels S, Macgrogan G, Kirkove C, Schmitt F, Servent V, Bellera C, Mathoulin-Pélissier S, Bonnetain F, Yarnold J, Wildiers H, van Tienhoven G, van der Hage J, Untch M, Thürlimann B, Jacot W, Gutowski M, Gligorov J, Bonnefoi H, Bogaerts J, Bliss J, A'Hern R, Cardoso F, Azria D, Asselain B, Poortmans P, Cameron D, Brain E, Cardoso M, Filleron T, Delaloge S, Debled M, De Azambuja E, Dalenc F, Dal Lago L, Cufer T, Coleman R, Chibaudel B, Gourgou-Bourgade S. Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials). Ann Oncol 2015
Oct 13, 2015Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)
Oct 13, 2015Ann Oncol 2015
Dabakuyo-Yonli T S, Russell N S, Roché H, Pruneri G, Penault Llorca F, Offersen B V, Negreiros I, Michiels S, Macgrogan G, Kirkove C, Schmitt F, Servent V, Bellera C, Mathoulin-Pélissier S, Bonnetain F, Yarnold J, Wildiers H, van Tienhoven G, van der Hage J A, Untch M, Thürlimann Beat, Jacot W, Gutowski M, Gligorov J, Bonnefoi H, Bogaerts J, Bliss J, A'Hern R, Cardoso F, Azria D, Asselain B, Poortmans P, Cameron D, Brain E, Cardoso M J, Filleron T, Delaloge S, Debled M, De Azambuja E, Dalenc F, Dal Lago L, Cufer T, Coleman R, Chibaudel B, Gourgou-Bourgade S
Thyroid cancers: which molecular markers are relevant?
Siano M (2015). Thyroid cancers: which molecular markers are relevant?.
Oct 10, 2015Thyroid cancers: which molecular markers are relevant?
Oct 10, 2015DGHO 2015
Siano Marco
Survival of recurrent/metastatic head and neck squamous cell cancer (r/mHNSCC) patients (pts) treated in 1st or 2nd line with an anti-EGFR-antibody (EAB)
Siano M (2015). Survival of recurrent/metastatic head and neck squamous cell cancer (r/mHNSCC) patients (pts) treated in 1st or 2nd line with an anti-EGFR-antibody (EAB). Presented at: DGHO 2015, Basel
Oct 10, 2015Survival of recurrent/metastatic head and neck squamous cell cancer (r/mHNSCC) patients (pts) treated in 1st or 2nd line with an anti-EGFR-antibody (EAB)
Oct 10, 2015DGHO 2015
Siano Marco
Systemic treatment pattern in a large cohort of recurrent/metastatic head and neck squamous cell cancer (r/m HNSCC) patients (pts) treated at a tertiary cancer centre
Siano M (2015). Systemic treatment pattern in a large cohort of recurrent/metastatic head and neck squamous cell cancer (r/m HNSCC) patients (pts) treated at a tertiary cancer centre. Presented at: DGHO 2015, -
Oct 10, 2015Systemic treatment pattern in a large cohort of recurrent/metastatic head and neck squamous cell cancer (r/m HNSCC) patients (pts) treated at a tertiary cancer centre
Oct 10, 2015DGHO 2015
Siano Marco
40 years of progress in female cancer death risk: a Bayesian spatio-temporal mapping analysis in Switzerland
Herrmann C, ess s, Thürlimann B, Probst-Hensch N, Vounatsou P. 40 years of progress in female cancer death risk: a Bayesian spatio-temporal mapping analysis in Switzerland. BMC cancer 2015; 15:666.
Oct 9, 201540 years of progress in female cancer death risk: a Bayesian spatio-temporal mapping analysis in Switzerland
Oct 9, 2015BMC cancer 2015; 15:666
Herrmann Christian, ess silvia, Thürlimann Beat, Probst-Hensch Nicole, Vounatsou Penelope
Site of metastatic disease influences adenoid cystic cancer (ACC) patients’ outcome
Cau M, Alfieri S, Siano M (2015). Site of metastatic disease influences adenoid cystic cancer (ACC) patients’ outcome.
Oct 9, 2015Site of metastatic disease influences adenoid cystic cancer (ACC) patients’ outcome
Oct 9, 2015AIOM
Cau MC, Alfieri S, Siano Marco
Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses
Ocana A, Pandiella A, Niraula S, Seruga B, Vera-Badillo F, Templeton A, Gascón-Escribano M, Srikanthan A, Corrales-Sanchez V, Diez-Gonzalez L, Ethier J, Amir E. Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses. Oncotarget 2015
Oct 4, 2015Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses
Oct 4, 2015Oncotarget 2015
Ocana Alberto, Pandiella Atanasio, Niraula Saroj, Seruga Bostjan, Vera-Badillo Francisco, Templeton Arnoud, Gascón-Escribano María J, Srikanthan Amirrtha, Corrales-Sanchez Verónica, Diez-Gonzalez Laura, Ethier Josee-Lyne, Amir Eitan
St.Gallen-2015 in Vienna: News from a successful breast cancer conference transposition!
Senn H, Thürlimann B, Gnant M. St.Gallen-2015 in Vienna: News from a successful breast cancer conference transposition!. Breast 2015
Oct 2, 2015St.Gallen-2015 in Vienna: News from a successful breast cancer conference transposition!
Oct 2, 2015Breast 2015
Senn Hans-Jörg, Thürlimann Beat, Gnant Michael
Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort
Gautschi O, Kerjouan M, Michels S, Pall G, Rothschild S, Schmid-Bindert G, Scheffler M, Veillon R, Wannesson L, Diebold J, Zalcman G, Filleron T, Huret B, Curioni-Fontecedro A, Milia J, Cabarrou B, Bluthgen M, Besse B, Smit E, Wolf J, Peters S, Früh M, Koeberle D, Oulkhouir Y, Schuler M, Mazières J. Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort. J Thorac Oncol 2015; 10:1451-7.
Oct 1, 2015Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort
Oct 1, 2015J Thorac Oncol 2015; 10:1451-7
Gautschi Oliver, Kerjouan Mallorie, Michels Sebastian, Pall Georg, Rothschild Sacha, Schmid-Bindert Gerald, Scheffler Matthias, Veillon Rémi, Wannesson Luciano, Diebold Joachim, Zalcman Gérard, Filleron Thomas, Huret Benjamin, Curioni-Fontecedro Alessandra, Milia Julie, Cabarrou Bastien, Bluthgen Marie-Virginia, Besse Benjamin, Smit Egbert F, Wolf Juergen, Peters Solange, Früh Martin, Koeberle Dieter, Oulkhouir Youssouf, Schuler Martin, Mazières Julien
Intranodal Mapping Using Carbon Dye Results in More Accurate Lymph Node Staging in Colon Cancer Patients
Weixler B, Warschkow R, Zettl A, Riehle H, Gueller U, Viehl C, Zuber M. Intranodal Mapping Using Carbon Dye Results in More Accurate Lymph Node Staging in Colon Cancer Patients. World J Surg 2015; 39:2583-9.
Oct 1, 2015Intranodal Mapping Using Carbon Dye Results in More Accurate Lymph Node Staging in Colon Cancer Patients
Oct 1, 2015World J Surg 2015; 39:2583-9
Weixler Benjamin, Warschkow Rene, Zettl Andreas, Riehle Hans-Martin, Gueller Ulrich, Viehl Carsten T, Zuber Markus